Literature DB >> 2734976

Difference in uptake of 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r.

M Hasenson1.   

Abstract

Estramustine, estradiol-3-N-bis(2-chloroethyl)carbamate (EM), has been shown to inhibit growth of the human prostatic carcinoma cell line LNCaP as well as its subline LNCaP-r. The hormone sensitive LNCaP showed greater sensitivity to the drug than the hormoneresistant LNCaP-r. LNCaP has also shown an increasing sensitivity to 10(-7) M EM, when incubated with different concentrations of steroid hormones. We studied whether the increasing sensitivity was caused by increased uptake of EM. 3H-estramustine was added to medium and the cells were incubated 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, and 4 h, or 2 h, 4 h, 6 h, and 8 h. No effect of steroids on the uptake of EM was noted, but LNCaP showed a higher uptake of EM compared to LNCaP-r. The uptake of EM in LNCaP increased for eight hours, whereas LNCaP-r reached its maximum uptake after six hours of incubation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2734976     DOI: 10.1007/bf00262029

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  6 in total

1.  Treatment of advanced prostatic carcinoma with Estracyt. A preliminary report.

Authors:  G Jönsson; B Högberg
Journal:  Scand J Urol Nephrol       Date:  1971

2.  Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r.

Authors:  M Hasenson; B Hartley-Asp; C Kihlfors; A Lundin; J A Gustafsson; A Pousette
Journal:  Prostate       Date:  1985       Impact factor: 4.104

3.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

4.  Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt).

Authors:  G Jönsson; B Högberg; T Nilsson
Journal:  Scand J Urol Nephrol       Date:  1977

5.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

6.  Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.

Authors:  M Hansenson; B Lundh; B Hartley-Asp; A Pousette
Journal:  Urol Res       Date:  1988
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.